NATICK, Mass., May 20 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the annual EuroPCR Scientific Program, May 25 – 28 in Paris.
"We are pleased to be announcing additional analyses from the SYNTAX trial, as well as clinical data supporting the performance of our TAXUS®, PROMUS® and PROMUS® Element™ drug-eluting stents," said Keith Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific's Cardiology, Rhythm and Vascular Group. "Our platinum chromium PROMUS Element Everolimus-Eluting Stent System continues to be well received by European physicians, and we are looking forward to launching the TAXUS® Element™ Paclitaxel-Eluting Stent System -- with a specific diabetic indication -- in CE Mark countries next month."
Schedule of Events (All times are Paris time; all events take place in the Palais des Congres.)
Tuesday, May 25
- PROMUS Stent in Diabetics. Eberhard Grube, M.D., will present one-year results from the SPIRIT V Diabetic substudy, during a late-breaking trial session at 1:54 p.m. in Room 252B. The substudy compares outcomes in diabetic patients treated with the XIENCE V® (PROMUS) Everolimus-Eluting Stent and the TAXUS® Liberte® Paclitaxel-Eluting Stent. SPIRIT V is a post-approval registry of the XIENCE V (PROMUS) Stent.
Wednesday, May 26
- SYNTAX-LE MANS Study. A. Pieter Kappetein, M.D., Ph.D., will present 24-month outcomes from an angiographic substudy of patients with left main disease from the SYNTAX trial, during an abstract session at 2:15 p.m. in Room 253. The SYNTAX trial compares percutaneous coronary intervention (PCI) using the TAXUS® Express2® Paclitaxel-Eluting Stent to coronary artery bypass graft (CABG) surgery in patients with left main disease and/or three-vessel disease.
Thursday, May 27
- Left Main Stenting in SYNTAX Trial. Marie-Claude Morice, M.D., will present two-year results from the SYNTAX trial evaluating repeat left main revascularization in patients with de novo left main disease treated with PCI using the TAXUS Express2 Paclitaxel-Eluting Stent. Results will be presented during an abstract session at 8:42 a.m. in Room 243.
- PROMUS Element Stent: Strut Coverage and Endothelial Cell Recovery. Nicole Soucy, M.D., will present results from a study comparing strut coverage and endothelial cell recovery in bare-metal and drug-eluting stents, including the PROMUS Element Everolimus-Eluting Stent, during an abstract session at 9:06 a.m. in Room 253.
- PROMUS Element Stent: Vascular Response. Gregory Wilson, M.D., and Barbara Huibregtse, D.V.M., will present results from a study of the vascular response to the PROMUS Element Everolimus-Eluting Stent, during an abstract session at 10:11 a.m. in Room 253.
- TAXUS Petal™ Bifurcation Stent: First Human Use. John Ormiston, M.D., will present results from the first human use of the TAXUS Petal Paclitaxel-Eluting Bifurcation Stent at 12:05 p.m. in Room 252A, during a plenary session that will feature the five best papers at EuroPCR 2010 as selected by the Editorial Board of EuroIntervention -- the official journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions.
- Symposium on Drug-Eluting Stents. The Company will host a symposium titled, "Designing the Future of Percutaneous Coronary Intervention - the Element Stent Technology and Beyond" from 12:00 to 1:30 p.m. in the Main Arena. The symposium will be chaired by Corrado Tamburino, M.D., and include presentations by Keith Dawkins, M.D., Ian Meredith, M.D., Bruno Farah, M.D., and Adrian Banning, M.D., on the new platinum chromium Element Stent platform and the future of drug-eluting stent technology.
Friday, May 28
- PROMUS® Stent: Two-Year Data. Bernard Chevalier, M.D., will present two-year clinical follow-up data from the SPIRIT V Registry evaluating the XIENCE V (PROMUS) Everolimus-Eluting Stent in real-world practice, during an abstract session at 11:35 a.m. in Room 252B.
Boston Scientific will present its latest cardiovascular products at booth #F17/18 in the Exhibit Hall. The Company will also sponsor two series of training sessions throughout the week in Room 353 titled "Endovascular Interventions – Carotid Arterial Stenting" and "Treatment Options for Complex Percutaneous Coronary Intervention."
TAXUS, Express2, Petal, PROMUS and Element are trademarks of Boston Scientific Corporation or its affiliates. The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. XIENCE V is a trademark of Abbott. The SPIRIT Clinical Program is sponsored by Abbott.
In the U.S., the PROMUS Element, TAXUS Element and TAXUS Petal systems are investigational devices and are limited by applicable law to investigational use only and are not available for sale. The safety and effectiveness of the TAXUS Express2 Stent System have not been established in patients with left main or three-vessel disease.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth strategies. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.